Administration of inhibitors of the NFκB activating enzyme (IKK2: inhibitory kappa-B kinase subunit beta) suppresses insulin resistance in diabetic mice [27], suggesting that suppression of NFκB signaling is a promising therapeutic target for the prevention and alleviation of inflammatory diseases, including metabolic syndrome. This evidence concerns the gene IKBKB and metabolic syndrome.